Data show SBT101 effectively delivered a functional copy of the ABCD1 gene to spinal cord tissues with resultant protein expression, addressing the underlying cause of disease and improving function ...

“These studies validate SBT101’s potential to be a first-in-class gene therapy for AMN, which could change the lives of thousands of people with this progressive and debilitating disease,” said ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented One presentation will summarize results from the ...

Baldurs Gate 3 received praise for its wide scope and world building, but Baldur's Gate 4 could expand even further by ...

After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 ...

BMO Capital lowered the firm’s price target on AMN Healthcare (AMN) to $46 from $50 and keeps an Outperform rating on the shares after ...

DALLAS - AMN Healthcare (NYSE:AMN), a provider of talent solutions for healthcare organizations, announced the upcoming addition of Tomya Watt to its executive team as Chief People Officer ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of AMN Healthcare Services Inc (Symbol: AMN) entered into oversold territory, hitting an RSI ...

First class is largely filled with corporate customers, but many deep-pocket individuals are willing to pay up as they demand ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...